Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172241 | 0.84 | LMNA (0.41) | LMNASMN1; SMN2KMT2AALDH1A1CACNA1H | |
| SCHEMBL2177475 | 0.78 | LMNA (0.43) | LMNASMN1; SMN2CYP19A1KMT2ACACNA1H | |
| SCHEMBL2172795 | 0.70 | CACNA1H (0.47) | LMNASMN1; SMN2ALDH1A1CACNA1HTSHR | |
| SCHEMBL1491108 | 0.66 | LMNA (0.55) | LMNASMN1; SMN2CYP19A1SLC2A1SIGMAR1 | |
| SCHEMBL185722 | 0.64 | CCR4 (0.54) | LMNASMN1; SMN2CYP19A1SLC2A1SIGMAR1 | |
| SCHEMBL9383041 | 0.62 | KDM4E (0.40) | SMN1; SMN2KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL30486002 | 0.62 | LMNA (0.52) | LMNASMN1; SMN2SLC2A1SIGMAR1KMT2A | |
| SCHEMBL19925941 | 0.60 | POLB (0.50) | LMNASMN1; SMN2KMT2AALDH1A1KDM4E | |
| SCHEMBL20421230 | 0.60 | CACNA1H (0.50) | LMNASMN1; SMN2CYP19A1SLC2A1SIGMAR1 | |
| SCHEMBL30644304 | 0.59 | ALDH1A1 (0.69) | LMNASMN1; SMN2CYP19A1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | LMNA 1122/4885SMN1; SMN2 2298/4885CYP19A1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.